comprehensive -WSS

comprehensive

author：entertainment 2025-09-03 14:37:31 - browse：22635

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： My yearlong odyssey to get my son’s ADHD medication covered

WSS

Humana cuts profit projections as Medicare Advantage costs soar

Report captures long Covid’s disabling effects and policy challenges

Statins may not be needed by millions of people, study suggests

Medical device trials still don't enroll enough women, study finds

ALS patient reclaims some autonomy thanks to wearable 'robot'

Francis Collins on trust in science and how Covid communications failed

focus

comprehensive

explore

Medical leaders decry Supreme Court decision on affirmative action

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

How to save PrEP access — and even expand it

NIH director takes cautious approach to Biden drug pricing priority

Guidelines to prevent youth baseball injuries need more muscle

Prior authorization will have to move faster under new Biden rule

The cancer drug shortage isn’t new — and neither are the solutions

Independent physicians launch a new lobbying group

Virginia high school admissions case could be legal follow

AI generated plenty of interest at JPM but not a lot of trust

explore

My daughter's legacy lives on through her writing, phage therapy

How digital therapeutics firms are pivoting after Pear's bankruptcy

'Essentially witchcraft:' A former naturopath takes on the field

Medical device trials still don't enroll enough women, study finds

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Think you might have Covid

focus

Wikipedia

hotspot

Wikipedia